PD-L1 >= 1%

About

Biomarker type: Protein expression

Marker: PD-L1

Unit: Tumor Proportion Score (TPS)

Equality: >=

Value: 0.01

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
EMA (1) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Durvalumab
EMA (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
EMA (2) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
EMA (2) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Pemetrexed
EMA (1) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
EMA (1) HSE (2) PD-L1 >= 1% Bladder Urothelial Carcinoma Nivolumab
EMA (2) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Ipilimumab, Nivolumab
EMA (1) HSE (2) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
EMA (1) HSE (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Nivolumab
EMA (1) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
HSE (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Docetaxel, Nivolumab